BioCentury
ARTICLE | Financial News

Ovid planning $86.3M IPO

April 11, 2017 7:57 PM UTC

Neurologic disease company Ovid Therapeutics Inc. (New York, N.Y.) proposed to raise $86.3 million in an IPO on NASDAQ underwritten by Citigroup, Cowen, William Blair and JMP Securities.

On Monday, Ovid said it began a Phase I trial of gaboxadol (OV101) in adolescents with Angelman syndrome or Fragile X syndrome. Gaboxadol, which is Ovid's lead candidate, is in Phase II testing to treat Angelman syndrome in adults. The candidate has Orphan Drug designation from FDA to treat Angelman syndrome...